Chronic hepatitis C tests help answer several questions: Is hepatitis C virus present now? Has the liver developed scarring? What needs checking before treatment? Did treatment achieve cure? An antibody result, viral load, or liver enzyme value cannot answer all of these questions.
Hepatitis C antibody testing looks for an immune response to the virus. HCV RNA testing looks for the virus's genetic material. Fibrosis assessment evaluates liver scarring, while appropriately timed RNA testing after antiviral treatment helps confirm cure. Ulta Lab Tests helps patients access relevant laboratory testing and bring results to their healthcare provider for interpretation.
Medical note: This article provides education, not an individual diagnosis or treatment plan. A qualified healthcare professional should select tests, interpret results, prescribe treatment, and arrange necessary imaging or specialist care.
For broader context, read Ulta's Liver Function Tests guide and Understanding Hepatitis Testing: Key Hepatitis Tests for A, B, and C.
Hepatitis C is a liver infection caused by hepatitis C virus, or HCV. It spreads through contact with infected blood. Infection that persists beyond the initial six months is generally described as chronic. Many people have no noticeable symptoms, even while liver damage develops. Fatigue, nausea, or joint discomfort can occur, but these symptoms have many other causes. 1
Over time, chronic infection can cause fibrosis, meaning scar tissue in the liver. Extensive scarring is called cirrhosis. HCV can also affect organs outside the liver, including the kidneys. Identifying infection creates an opportunity for treatment before complications develop.
Modern direct-acting antiviral medicines cure more than 95% of people with hepatitis C, often with an 8- to 12-week course. That is a population-level treatment outcome, not a guarantee for an individual. A positive result should lead to medical care rather than indefinite viral-load monitoring without a treatment plan. 2
CDC recommends screening at least once for adults aged 18 and older and during each pregnancy, with additional testing for ongoing risks or suspected exposure. Testing remains appropriate even when someone feels well. The initial screening strategy differs from testing after a previous infection. 3
| Situation or finding | Why it matters | Testing discussion |
|---|---|---|
| No previous adult screening | Infection may be silent | HCV antibody with automatic reflex RNA when reactive |
| Recent blood exposure, shared injection equipment, or occupational exposure | Antibodies may not yet be detectable | HCV RNA and clinician-directed follow-up |
| Prior transfusion or transplant before modern screening, or ongoing dialysis | Exposure history can change testing needs | Initial screening or repeat testing based on history |
| Unexplained elevated liver enzymes or persistent symptoms | HCV is one possible cause | HCV testing plus appropriate liver assessment |
| Previous HCV infection or cure with a new exposure | Antibodies may remain positive | HCV RNA rather than another antibody screen |
| Pregnancy | Maternal infection requires coordinated care | Screening each pregnancy; RNA and liver tests if antibody positive |
Severe symptoms require medical evaluation, not a routine online test order. Vomiting blood, black stools with weakness, or new confusion warrant emergency care. New jaundice, abdominal swelling, or rapidly worsening illness needs prompt assessment.
HCV antibody indicates possible past or current exposure; HCV RNA establishes whether virus is detected in the sample. Reflex testing means the laboratory automatically performs the next test when the initial result meets specified criteria.
| HCV antibody | HCV RNA | Usual interpretation | Important next step |
|---|---|---|---|
| Nonreactive | Not performed | No antibody evidence of infection | Consider RNA if exposure was recent or immune suppression may affect antibody production |
| Reactive | Detected | Current HCV infection | Medical evaluation, confirmation as appropriate, fibrosis assessment, and treatment planning |
| Reactive | Not detected | No evidence of current infection in that sample | Consider resolved infection, previous cure, or false-positive antibody; repeat RNA in selected circumstances |
| Nonreactive | Detected | Possible early infection before antibodies develop | Prompt clinician review and appropriate confirmation |
Recent exposure, symptoms, and specimen concerns can change the follow-up plan. CDC recommends confirming RNA positivity in a subsequent blood sample before antiviral treatment. This is different from repeating antibody testing. 3
A reactive antibody and detectable RNA do not establish how long infection has been present. Previous negative tests, exposure timing, and earlier results help distinguish recent from chronic infection. Clinicians do not need to wait for infection to become chronic before considering treatment. 2
Quantitative HCV RNA measures circulating virus, usually reported in international units per milliliter, or IU/mL. Some reports also show a logarithmic value. Neither number is a score for liver damage.
A person with a high viral load may have limited scarring, while someone with a lower viral load may have advanced liver disease. Fibrosis therefore requires separate assessment. Normal liver enzymes also cannot substitute for HCV testing or exclude significant liver disease. 4
Read the laboratory's wording carefully. “Not detected” differs from “detected below the lower limit of quantification.” The latter means a viral signal was found but is too low for reliable numerical measurement. A bare “less than” value needs its accompanying interpretation. Treatment timing and the assay's reporting conventions matter when evaluating cure. 5
Fibrosis assessment helps determine whether cirrhosis is present and what monitoring will remain necessary after treatment. It combines laboratory results with medical history, examination, and sometimes imaging or elastography, which measures liver stiffness.
FIB-4 is a calculated score using age, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and platelet count. It is not a direct measurement of scar tissue. The numerator is age multiplied by AST; the denominator is platelet count multiplied by the square root of ALT. Use age in years, enzymes in U/L, and platelets in billions per liter.
In the AASLD/IDSA simplified HCV pathway, a FIB-4 above 3.25 is one criterion used to presume cirrhosis. Other evidence includes compatible elastography, previous biopsy, liver nodularity, an enlarged spleen, or low platelets. These are pathway criteria, not universal self-diagnosis rules. A lower score does not override other concerning findings. 6
Age, acute illness, muscle injury, or a platelet disorder can distort interpretation. Elastography may clarify uncertainty; biopsy is not routinely required for everyone. Liver chemistry and fibrosis findings should be reviewed together. Suspected decompensated cirrhosis, where complications indicate impaired liver function, requires specialist care. 4
Pretreatment testing establishes infection status, liver and kidney health, and relevant coinfections. The following tests have different roles; this is not a shopping list for every reader.
| Test or biomarker | What it measures | Role and general interpretation | Main limitation |
|---|---|---|---|
| Hepatitis C Antibody Test with Reflex to RNA Quantitative PCR | Antibodies, followed by viral RNA when reflex criteria are met | Initial screening; reactive antibody requires RNA interpretation | Does not independently establish duration or fibrosis |
| Hepatitis C Viral RNA, Quantitative, Real-Time PCR | Amount of circulating HCV RNA | Current infection, baseline assessment, cure testing, or recurrence evaluation | Viral load does not measure scarring |
| Hepatic Function Panel | Enzymes, bilirubin, albumin, and proteins | Elevated enzymes may indicate injury; bilirubin or albumin abnormalities need context | Normal values do not exclude fibrosis; abnormalities have other causes |
| Complete Blood Count with Differential and Platelets | Blood cells, hemoglobin, and platelets | Low platelets may support concern about advanced disease; anemia may affect care | Blood-cell changes are not specific to HCV |
| Creatinine with estimated glomerular filtration rate, or eGFR | Kidney filtration estimate | Lower eGFR may change assessment or monitoring needs | Muscle mass, illness, and other factors affect interpretation |
| Prothrombin Time with INR | Clotting time | Prolongation may contribute to liver-function assessment, particularly with cirrhosis | Anticoagulants, vitamin K status, and other factors influence results |
| FIB-4 calculation | Age plus AST, ALT, and platelets | Estimates likelihood of advanced fibrosis | Requires appropriate context and sometimes secondary assessment |
| HBsAg, total anti-HBc, and anti-HBs | Hepatitis B antigen and antibody pattern | Identifies current or previous HBV exposure and susceptibility questions before HCV therapy | The three markers must be read together |
| HIV antigen/antibody testing | Evidence of HIV infection | Identifies coinfection relevant to care and drug interactions | A reactive screen requires the appropriate confirmation sequence |
| HCV genotype testing | Viral genotype | Selected treatment-planning or retreatment questions | Not universally required with pangenotypic treatment |
Eligible adults without cirrhosis commonly need a recent blood count, hepatic panel, and eGFR, plus baseline RNA and relevant infection screening. Cirrhosis changes the pathway and may require more recent laboratory results, INR, and liver ultrasound. Review existing results before duplicating tests. 6 7
HBV screening includes hepatitis B surface antigen (HBsAg), total hepatitis B core antibody (anti-HBc), and hepatitis B surface antibody (anti-HBs). Hepatitis B can reactivate during HCV treatment. A positive HBsAg result requires additional HBV assessment and a management plan. Vaccination against hepatitis A or B may be appropriate for susceptible patients. 2
Genotype testing is conditional. People without cirrhosis who have never received treatment may use a pangenotypic regimen without genotype testing, while other circumstances require it. A clinician also reviews prescription medicines, supplements, previous treatment, pregnancy, and interactions. 4
Monitoring focuses on medication use, interactions, symptoms, and specific safety needs. Routine HCV RNA testing during uncomplicated therapy is generally unnecessary. Detectable RNA early in treatment does not, by itself, establish failure or justify stopping medication. 8
People taking diabetes medicines may need closer glucose monitoring because glucose levels can improve during therapy. Warfarin users may need INR monitoring. Follow the treating clinician's plan; do not change medication in response to this article or a single result. 6
SVR12 means sustained virologic response assessed at least 12 weeks after treatment ends. Undetectable or nonquantifiable HCV RNA at that time is consistent with cure. The interval starts with the last treatment dose, not the first. Antibody testing cannot confirm cure.
Current AASLD/IDSA guidance also allows consideration of SVR4, measured four weeks after treatment, as an alternative in selected people without cirrhosis or previous direct-acting antiviral exposure, particularly when later follow-up may be difficult. This does not make every early negative result a cure assessment. The treating clinician should select the timing and interpret the complete RNA report. 8
Record the treatment end date, test date, and result together. If the planned cure test is missed, contact the care team to arrange follow-up.
Follow-up depends on cirrhosis, ongoing exposure, and other liver disease. These are separate reasons for continued care:
People without cirrhosis, another liver disorder, or ongoing exposure generally do not need continued HCV-specific liver follow-up after cure. 8 7
Ulta's MASLD blood-testing guide explains a common coexisting cause of liver abnormalities. Viral cure should not be interpreted as proof that every liver problem has resolved.
HCV can contribute to immune-complex disease, including cryoglobulinemic vasculitis. Purplish skin spots, nerve symptoms, swelling, or protein in urine may justify kidney testing, urine assessment, and specialist-directed cryoglobulin or complement testing. These are targeted investigations, not routine additions for every person with HCV. 9
Pregnancy also requires coordinated care. Antibody-positive pregnant patients should have RNA and liver testing assessed during prenatal care. Treatment before pregnancy is preferred when feasible; treatment during pregnancy requires an individualized specialist discussion. Pregnancy testing may be part of pretreatment assessment when relevant. 10
Before collection, review the exact test instructions and your clinician's order. HCV antibody and RNA tests usually do not require fasting, but accompanying tests may. Bring the required identification and requisition, and share previous results and treatment dates.
Use the laboratory's reference intervals, units, detection limits, and comments. There is no separate wellness target for an HCV antibody level. Trends are most useful when dates and methods are comparable. Tell your clinician about recent illness, strenuous exercise, pregnancy, supplements, and medicines; these may affect accompanying liver, kidney, or blood-count findings.
Bring the full laboratory reports and use these questions to clarify next steps:
Ulta Lab Tests offers online access to many laboratory tests where available, with pricing shown before ordering. Testing is performed through established laboratory networks such as Quest Diagnostics where applicable. No insurance is required; eligible HSA or FSA payment may be available, and results are delivered through a secure online account.
Review the exact test components, preparation instructions, and any additional reflex-testing charges. Share results with a qualified healthcare provider who can arrange treatment and imaging when needed. For background on testing methods and timing, see Infectious Disease Testing.
AASLD/IDSA's June 2026 point-of-care algorithm supports linking diagnosis to treatment in appropriate clinical settings. This approach requires locally available services and a treating clinician. 11
Yes. An antibody test can be negative early after infection, before the immune response develops. Immune suppression can also affect antibody detection. If exposure was recent, discuss HCV RNA testing and follow-up with a clinician rather than assuming a negative antibody result settles the question.
Antibodies can persist as evidence of an earlier immune response after the virus has cleared. A reactive antibody result alone does not mean treatment failed. Post-treatment RNA testing, interpreted at the appropriate time, establishes the response to therapy. RNA is also used when reinfection is suspected.
No. Viral load measures circulating virus, while liver scarring is assessed separately. Clinicians may use FIB-4, platelet count, elastography, imaging, and other findings to evaluate fibrosis. A lower viral load does not establish a healthier liver, and normal enzymes do not replace a fibrosis assessment.
No. ALT and AST reflect liver-cell injury and can vary over time. They do not establish whether HCV is present, and normal values do not exclude important liver disease. Use the appropriate antibody-to-RNA testing sequence for infection status, with a separate assessment of fibrosis when indicated.
An end-of-treatment result is encouraging, but it is not the usual post-treatment cure assessment. SVR12 is measured at least 12 weeks after the last dose. Selected patients may qualify for SVR4 under current guidance. Ask the treating clinician which timing applies before deciding follow-up is complete.
No. Pangenotypic medicines treat multiple HCV genotypes, and some treatment-naive adults without cirrhosis do not need genotype testing before using them. Genotype can still matter in other treatment pathways or after previous treatment failure. The clinician selects testing based on the intended regimen and clinical history.
A person can acquire a new HCV infection because previous infection does not provide reliable immunity. Late relapse is uncommon but can occur. New exposure, ongoing risk, or unexplained liver dysfunction may prompt RNA testing. Repeating an antibody test does not distinguish previous infection from reinfection.
Ulta Lab Tests provides online access to relevant testing where available. The appropriate order depends on whether the question is initial screening, current infection, or follow-up after treatment. Review the product's components and reflex conditions, and arrange clinician interpretation and care if a result is reactive or detected.
Chronic hepatitis C tests are most useful when each result leads to a defined next step. Explore relevant testing with Ulta Lab Tests, review existing results to avoid duplication, and work with a qualified healthcare provider on confirmation, fibrosis assessment, treatment, and follow-up. Keep the planned cure-test date with your treatment records.
Clinical sources checked September 10, 2026.
| Category | Test and candidate Ulta destination | Role in the article |
|---|---|---|
| Initial screening | Hepatitis C Antibody Test with Reflex to RNA Quantitative PCR | Antibody screening followed by RNA when reflex criteria are met |
| Current infection and follow-up | Hepatitis C Viral RNA, Quantitative, Real-Time PCR | Confirmation, baseline assessment, cure testing, and recurrence evaluation |
| Liver assessment | Hepatic Function Panel | Liver enzymes, bilirubin, albumin, and protein findings |
| Blood cells and platelets | Complete Blood Count with Differential and Platelets | Blood-count assessment and platelet information |
| Kidney assessment | Creatinine Test | Kidney-function context; confirm current eGFR reporting |
| Selected liver-function assessment | Prothrombin Time with INR | Clotting assessment, particularly when cirrhosis is relevant |
| Hepatitis B assessment | Hepatitis B Surface Antigen Test with Reflex to Confirmation | HBsAg component of pretreatment HBV assessment |
| Hepatitis B assessment | Hepatitis B Core Antibody, Total | Evidence of previous or current natural HBV exposure |
| Hepatitis B assessment | Hepatitis B Surface Antibody, Quantitative | Anti-HBs component of the combined HBV pattern |
| Selected treatment planning | Hepatitis C Viral RNA Genotype, LiPA | Genotype assessment when the treatment pathway requires it |
| Selected cirrhosis surveillance | Alpha-Fetoprotein Tumor Marker Test | Potential adjunct to liver imaging; not a replacement for imaging |
| Priority | Related Health Area | Relationship to the article |
|---|---|---|
| 1 | Hepatitis | Viral hepatitis testing |
| 2 | Cirrhosis | Advanced scarring and continued surveillance |
| 3 | All Liver Tests | Liver chemistry and broader assessment |
| 4 | Infectious Disease Testing | Infection detection and coinfection context |
Ulta Lab Tests, LLC.
9237 E Via de Ventura, Suite 220
Scottsdale, AZ 85258
480-681-4081
(Toll Free: 800-714-0424)
